Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for ret… Read more
Carl Zeiss Meditec AG (CZMWF) - Net Assets
Latest net assets as of September 2025: $2.19 Billion USD
Based on the latest financial reports, Carl Zeiss Meditec AG (CZMWF) has net assets worth $2.19 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.47 Billion) and total liabilities ($1.28 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.19 Billion |
| % of Total Assets | 63.19% |
| Annual Growth Rate | 12.34% |
| 5-Year Change | 26.85% |
| 10-Year Change | 149.98% |
| Growth Volatility | 23.99 |
Carl Zeiss Meditec AG - Net Assets Trend (2006–2025)
This chart illustrates how Carl Zeiss Meditec AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Carl Zeiss Meditec AG (2006–2025)
The table below shows the annual net assets of Carl Zeiss Meditec AG from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $2.13 Billion | +3.46% |
| 2024-09-30 | $2.06 Billion | -5.36% |
| 2023-09-30 | $2.17 Billion | +7.03% |
| 2022-09-30 | $2.03 Billion | +21.03% |
| 2021-09-30 | $1.68 Billion | +15.64% |
| 2020-09-30 | $1.45 Billion | +2.37% |
| 2019-09-30 | $1.42 Billion | +7.78% |
| 2018-09-30 | $1.31 Billion | +5.87% |
| 2017-09-30 | $1.24 Billion | +45.89% |
| 2016-09-30 | $851.16 Million | +6.74% |
| 2015-09-30 | $797.45 Million | +5.73% |
| 2014-09-30 | $754.23 Million | +2.64% |
| 2013-09-30 | $734.84 Million | +5.61% |
| 2012-09-30 | $695.80 Million | +9.74% |
| 2011-09-30 | $634.07 Million | +5.86% |
| 2010-09-30 | $598.98 Million | +10.97% |
| 2009-09-30 | $539.77 Million | +7.80% |
| 2008-09-30 | $500.73 Million | +4.05% |
| 2007-09-30 | $481.25 Million | +106.39% |
| 2006-09-30 | $233.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Carl Zeiss Meditec AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11223.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.85 Billion | 87.33% |
| Common Stock | $104.95 Million | 4.96% |
| Other Comprehensive Income | $-21.25 Million | -1.00% |
| Other Components | $184.50 Million | 8.72% |
| Total Equity | $2.12 Billion | 100.00% |
Carl Zeiss Meditec AG Competitors by Market Cap
The table below lists competitors of Carl Zeiss Meditec AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Western Securities Co Ltd
SHE:002673
|
$2.22 Billion |
|
L&F Co. Ltd
KQ:066970
|
$2.22 Billion |
|
BANK MILLENNIUM ZY 1
F:1HN
|
$2.23 Billion |
|
EO Technics Co. Ltd
KQ:039030
|
$2.23 Billion |
|
MC GRATH RENT DL-01
F:MG8
|
$2.22 Billion |
|
Liquidia Technologies Inc
NASDAQ:LQDA
|
$2.22 Billion |
|
Zhongfu Straits Pingtan Development Co Ltd
SHE:000592
|
$2.22 Billion |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SHE:000636
|
$2.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Carl Zeiss Meditec AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,041,697,000 to 2,116,506,000, a change of 74,809,000 (3.7%).
- Net income of 141,210,000 contributed positively to equity growth.
- Dividend payments of 61,631,415 reduced retained earnings.
- Other comprehensive income decreased equity by 17,019,651.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $141.21 Million | +6.67% |
| Dividends Paid | $61.63 Million | -2.91% |
| Other Comprehensive Income | $-17.02 Million | -0.8% |
| Other Changes | $12.25 Million | +0.58% |
| Total Change | $- | 3.66% |
Book Value vs Market Value Analysis
This analysis compares Carl Zeiss Meditec AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.88x to 2.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-09-30 | $6.32 | $68.73 | x |
| 2006-09-30 | $6.86 | $68.73 | x |
| 2007-09-30 | $6.05 | $68.73 | x |
| 2008-09-30 | $6.00 | $68.73 | x |
| 2009-09-30 | $6.41 | $68.73 | x |
| 2010-09-30 | $7.04 | $68.73 | x |
| 2011-09-30 | $7.37 | $68.73 | x |
| 2012-09-30 | $8.06 | $68.73 | x |
| 2013-09-30 | $8.59 | $68.73 | x |
| 2014-09-30 | $8.80 | $68.73 | x |
| 2015-09-30 | $9.27 | $68.73 | x |
| 2016-09-30 | $9.81 | $68.73 | x |
| 2017-09-30 | $14.20 | $68.73 | x |
| 2018-09-30 | $14.46 | $68.73 | x |
| 2019-09-30 | $15.64 | $68.73 | x |
| 2020-09-30 | $16.01 | $68.73 | x |
| 2021-09-30 | $18.55 | $68.73 | x |
| 2022-09-30 | $22.53 | $68.73 | x |
| 2023-09-30 | $24.14 | $68.73 | x |
| 2024-09-30 | $22.98 | $68.73 | x |
| 2025-09-30 | $24.18 | $68.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Carl Zeiss Meditec AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.67%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.40%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.61x
- Recent ROE (6.67%) is below the historical average (11.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 11.96% | 6.83% | 1.01x | 1.74x | $4.38 Million |
| 2007 | 10.53% | 8.71% | 0.82x | 1.48x | $2.49 Million |
| 2008 | 11.53% | 9.37% | 0.84x | 1.47x | $7.44 Million |
| 2009 | 10.58% | 8.61% | 0.85x | 1.45x | $3.02 Million |
| 2010 | 10.41% | 8.81% | 0.80x | 1.47x | $2.37 Million |
| 2011 | 11.17% | 8.82% | 0.87x | 1.45x | $7.00 Million |
| 2012 | 10.97% | 8.34% | 0.90x | 1.47x | $6.37 Million |
| 2013 | 13.19% | 10.16% | 0.92x | 1.40x | $22.29 Million |
| 2014 | 10.48% | 8.24% | 0.88x | 1.45x | $3.43 Million |
| 2015 | 8.26% | 5.99% | 0.91x | 1.51x | $-13.09 Million |
| 2016 | 12.32% | 9.03% | 0.87x | 1.56x | $18.55 Million |
| 2017 | 11.06% | 11.30% | 0.73x | 1.34x | $12.91 Million |
| 2018 | 9.78% | 9.87% | 0.77x | 1.28x | $-2.88 Million |
| 2019 | 11.42% | 10.95% | 0.72x | 1.45x | $19.91 Million |
| 2020 | 8.55% | 9.16% | 0.66x | 1.41x | $-20.79 Million |
| 2021 | 14.24% | 14.35% | 0.69x | 1.44x | $70.34 Million |
| 2022 | 14.59% | 15.45% | 0.67x | 1.40x | $92.40 Million |
| 2023 | 13.45% | 13.90% | 0.69x | 1.40x | $74.45 Million |
| 2024 | 8.75% | 8.65% | 0.61x | 1.66x | $-25.44 Million |
| 2025 | 6.67% | 5.40% | 0.77x | 1.61x | $-70.44 Million |
Industry Comparison
This section compares Carl Zeiss Meditec AG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Carl Zeiss Meditec AG (CZMWF) | $2.19 Billion | 11.96% | 0.58x | $2.22 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |